Screener
Spyre Therapeutics, Inc. SYRE Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Series B non-voting convertible preferred stock, $0.0001 par value; 271,625 shares authorized and 16,667 shares issued and outstanding as of March 31, 2026 and December 31, 2025. | 9,395 | 9,395 |
| Preferred stock, $0.0001 par value; 8,642,034 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025. | — | — |
| Common stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 78,839,858 shares and 78,189,811 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | 15 | 15 |
| Additional paid-in capital | 1,712,383 | 1,686,167 |
| Accumulated other comprehensive (loss) income | (767) | 869 |
| Accumulated deficit | (1,196,640) | (1,127,635) |
| TOTAL STOCKHOLDERS’ EQUITY | 670,811 | 715,236 |
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | $763,953 | $777,781 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s retained earnings?
- Spyre Therapeutics, Inc. (SYRE) reported retained earnings of -$1.2B in Q1 2026.
- How has Spyre Therapeutics, Inc.'s retained earnings changed year-over-year?
- Spyre Therapeutics, Inc.'s retained earnings decreased by 17.6% year-over-year, from -$1.02B to -$1.2B.
- What is the long-term trend for Spyre Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s retained earnings has grown at a 32.5% compound annual growth rate (CAGR), from -$276.01M to -$1.13B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Spyre Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude